Sigma has had a busy day. It's unveiled a new visual identity for its brand, alongside announcements of a new mirrorless ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
GlobalData on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Creative Bloq on MSN1d
From McDonald's to Kellogg's: Why are so many brands ditching their logo?While nostalgia might tempt consumers to resist change, savvy brands know they must continuously evolve, particularly in ...
Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback